Alectinib (Alecensa)

Alectinib (Alecensa) is an oral, targeted tyrosine kinase inhibitor approved to treat ALK-positive, metastatic, or early-stage (adjuvant) non-small cell lung cancer (NSCLC). It works by blocking the ALK protein, preventing cancer growth, and is often used as a first-line treatment. Common side effects include constipation, fatigue, edema, muscle pain, and rash